Xu Rong, Hong Huynh A, Khandaker Shadia, Baltazar Murielle, Allehyani Noor, Beentjes Daan, Prince Tessa, Ho Yen-Linh, Nguyen Linh Hanh, Hynes Daniel, Love William, Cutting Simon M, Kadioglu Aras
Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, United Kingdom.
SporeGen Ltd., London Bioscience Innovation Centre, London, United Kingdom.
Front Immunol. 2025 Apr 2;16:1501907. doi: 10.3389/fimmu.2025.1501907. eCollection 2025.
Spores of the bacterium () have been shown to carry a number of properties potentially beneficial for vaccination. Firstly, as vehicles enabling mucosal delivery of heterologous antigens and secondly, as stimulators of innate immunity. Here, we have examined the specificity of protection conferred by the spore-induced innate response, focusing on influenza H1N1, respiratory syncytial virus (RSV), and coronavirus-2 (SARS-CoV-2) infections.
viral challenge murine models were used to assess the prophylactic anti-viral effects of spores delivered by intranasal instilling, using an optimised three-dose regimen. Multiple nasal boosting doses following intramuscular priming with SARS-CoV-2 spike protein was also tested for the capability of spores on enhancing the efficacy of parenteral vaccination. To determine the impact of spores on immune cell trafficking to lungs, we used intravascular staining to characterise cellular participants in spore-dosed pulmonary compartments (airway and lung parenchyma) before and after viral challenge.
We found that mice pre-treated with spores developed resistance to all three pathogens and, in each case, exhibited a significant improvement in both survival rate and disease severity. Intranasal spore dosing expanded alveolar macrophages and induced recruitment of leukocyte populations, providing a cellular mechanism for the protection. Most importantly, virus-induced inflammatory leukocyte infiltration was attenuated in spore-treated lungs, which may alleviate the associated collateral tissue damage that leads to the development of severe conditions. Remarkably, spores were able to promote the induction of tissue-resident memory T cells, and, when administered following an intramuscular prime with SARS-CoV-2 spike protein, increased the levels of anti-spike IgA and IgG in the lung and serum.
Taken together, our results show that spores are able to regulate both innate and adaptive immunity, providing heterologous protection against a variety of important respiratory viruses of high global disease burden.
已证明细菌()的孢子具有许多可能对疫苗接种有益的特性。首先,作为能够实现异源抗原黏膜递送的载体,其次,作为先天免疫的刺激物。在此,我们研究了孢子诱导的先天反应所赋予的保护特异性,重点关注甲型H1N1流感病毒、呼吸道合胞病毒(RSV)和新型冠状病毒2(SARS-CoV-2)感染。
使用病毒攻击小鼠模型,采用优化的三剂量方案,通过鼻内滴注评估孢子的预防性抗病毒作用。还测试了用SARS-CoV-2刺突蛋白进行肌肉注射初免后多次鼻内加强剂量的孢子增强胃肠外疫苗接种效果的能力。为了确定孢子对免疫细胞向肺部迁移的影响,我们使用血管内染色来表征病毒攻击前后孢子给药的肺区室(气道和肺实质)中的细胞参与者。
我们发现,用孢子预处理的小鼠对所有三种病原体都产生了抗性,并且在每种情况下,存活率和疾病严重程度均有显著改善。鼻内给予孢子可使肺泡巨噬细胞增多并诱导白细胞群体募集,提供了一种保护的细胞机制。最重要的是,在经孢子处理的肺中,病毒诱导的炎性白细胞浸润减弱,这可能减轻导致严重疾病发生的相关附带组织损伤。值得注意的是,孢子能够促进组织驻留记忆T细胞的诱导,并且在用SARS-CoV-2刺突蛋白进行肌肉注射初免后给予孢子时,可增加肺和血清中抗刺突IgA和IgG的水平。
综上所述,我们的结果表明,孢子能够调节先天免疫和适应性免疫,针对多种全球疾病负担高的重要呼吸道病毒提供异源保护。